Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) represent a promising therapeutic approach for cancer patients by combining the antigen-targeting specificity of monoclonal antibodies (mAbs) with the cytotoxic potency of chemotherapeutic drugs.  In Antibody-Drug Conjugates, expert researchers provide detailed protocols for many of the key ADC techniques necessary for working in the field. These chapters and methodologies are aimed at the key tasks necessary to identify a suitable target, properly design the mAb, the linker and the payload, as well as to conjugate them in a reproducible and scalable fashion.  Written in the highly successful Methods in Molecular Biology™ format, these detailed chapters include the kind of practical implementation advice that guarantees quality results.

Antibody-Drug Conjugate (ADC) Clinical Pipeline: A Review.- Antibody-Drug Conjugate Target Selection: Critical Factors.- Selecting an Optimal Antibody for Antibody-Drug Conjugate Therapy: Internalization and Intracellular Localization.- Antibody-Drug Conjugate Payloads.- Linker Technologies for Antibody-Drug Conjugates.- In Vivo Testing of Drug-Linker Stability.- Pharmacokinetics and ADME Characterizations of Antibody-Drug Conjugates.- Safe Handling of Cytotoxic Compounds in a Biopharmaceutical Environment.- Micro- and Mid-Scale Maleimide-Based Conjugation of Cytotoxic Drugs to Antibody Hinge Region Thiols for Tumor Targeting.- Protocols for Lysine Conjugation.- Engineering THIOMABs for Site-Specific Conjugation of Thiol-Reactive Linkers.- Enzymatic Antibody Modification by Bacterial Transglutaminase.- Formulation Development of Antibody-Drug Conjugates.- Conjugation Process Development and Scale-Up.- Methods for Conjugating Antibodies to Nanocarriers.- Drug-to-Antibody Ratio (DAR) by UV/Vis Spectroscopy.- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by Hydrophobic Interaction Chromatography and Reversed Phase High Performance Liquid Chromatography.- Drug-to-Antibody Ratio (DAR) and Drug Load Distribution by LC-ESI-MS.- Determination of Charge Heterogeneity and Level of Unconjugated Antibody by Imaged cIEF.- Risk-Based Scientific Approach for Determination of Extractables/Leachables from Biomanufacturing of Antibody-Drug Conjugates (ADCs).